The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation

Jean-Charles Fruchart, Raul D. Santos, Carlos Aguilar-Salinas, Masanori Aikawa, Khalid Al Rasadi, Pierre Amarenco, Philip J. Barter, Richard Ceska, Alberto Corsini, Jean-Pierre Despres, Patrick Duriez, Robert H. Eckel, Marat V. Ezhov, Michel Farnier, Henry N. Ginsberg, Michel P. Hermans, Shun Ishibashi, Fredrik Karpe, Tatsuhiko Kodama, Wolfgang KoenigMichel Krempf, Soo Lim, Alberto J. Lorenzatti, Ruth McPherson, Jesus Millan Nunez-Cortes, Borge G. Nordestgaard, Hisao Ogawa, Chris J. Packard, Jorge Plutzky, Carlos I. Ponte-Negretti, Aruna Pradhan, Kausik K. Ray, Zeljko Reiner, Paul M. Ridker, Massimiliano Ruscica, Shaukat Sadikot, Hitoshi Shimano, Piyamitr Sritara, Jane K. Stock, Ta-Chen Su, Andrey V. Susekov, Andre Tartar, Marja-Riitta Taskinen, Alexander Tenenbaum, Lale S. Tokgozoglu, Brian Tomlinson, Anne Tybjaerg-Hansen, Paul Valensi, Michal Vrablik, Walter Wahli, Gerald F. Watts, Shizuya Yamashita, Koutaro Yokote, Alberto Zambon, Peter Libby

Forskningsoutput: TidskriftsbidragÖversiktsartikelPeer review

Originalspråkengelska
Artikelnummer71
TidskriftCardiovascular Diabetology
Volym18
Antal sidor20
ISSN1475-2840
DOI
StatusPublicerad - 4 jun 2019
MoE-publikationstypA2 Granska artikel i en vetenskaplig tidskrift

Vetenskapsgrenar

  • 3121 Inre medicin

Citera det här